IBDEI0Z8 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15903,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,15903,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,15903,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,15904,0)
 ;;=L40.3^^61^765^295
 ;;^UTILITY(U,$J,358.3,15904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15904,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,15904,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,15904,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,15905,0)
 ;;=L40.4^^61^765^160
 ;;^UTILITY(U,$J,358.3,15905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15905,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,15905,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,15905,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,15906,0)
 ;;=L40.8^^61^765^292
 ;;^UTILITY(U,$J,358.3,15906,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15906,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,15906,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,15906,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,15907,0)
 ;;=L40.9^^61^765^294
 ;;^UTILITY(U,$J,358.3,15907,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15907,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,15907,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,15907,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,15908,0)
 ;;=L50.9^^61^765^326
 ;;^UTILITY(U,$J,358.3,15908,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15908,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,15908,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,15908,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,15909,0)
 ;;=L53.8^^61^765^150
 ;;^UTILITY(U,$J,358.3,15909,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15909,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,15909,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,15909,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,15910,0)
 ;;=L53.9^^61^765^149
 ;;^UTILITY(U,$J,358.3,15910,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15910,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,15910,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,15910,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,15911,0)
 ;;=L54.^^61^765^148
 ;;^UTILITY(U,$J,358.3,15911,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15911,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,15911,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,15911,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,15912,0)
 ;;=L56.0^^61^765^142
 ;;^UTILITY(U,$J,358.3,15912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15912,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,15912,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,15912,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,15913,0)
 ;;=L56.1^^61^765^141
 ;;^UTILITY(U,$J,358.3,15913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15913,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,15913,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,15913,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,15914,0)
 ;;=L56.2^^61^765^274
 ;;^UTILITY(U,$J,358.3,15914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15914,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,15914,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,15914,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,15915,0)
 ;;=L56.3^^61^765^308
 ;;^UTILITY(U,$J,358.3,15915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15915,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,15915,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,15915,2)
 ;;=^5009217
